Navigation Links
Vermillion Reports First Quarter 2013 Results
Date:5/15/2013

forward-looking statements are based on Vermillion's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty as to Vermillion's ability to protect and promote its proprietary technology; (2) Vermillion's lack of a lengthy track record successfully developing and commercializing diagnostic products; (3) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its future diagnostic products; (4) uncertainty of the size of market for its existing diagnostic tests or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payers such as private insurance companies and government insurance plans; (5) uncertainty that Vermillion has sufficient cash resources to fully commercialize its tests and continue as a going concern; (6) uncertainty whether the trading in Vermillion's stock will become significantly less liquid; and (7) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission. All information in this press release is as of the date of this report, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law.


'/>"/>

SOURCE Vermillion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Vermillion Sharpens Focus and Streamlines Operations in 2012
2. Vermillion Reports Fourth Quarter and Full Year 2011 Results
3. Vermillion Reports First Quarter 2012 Results
4. Concerned Stockholders Launch Save Vermillion! Website: www.savevrml.com
5. Vermillion to Participate in Lazard Capital Markets 5th Annual Medical Technology Snowbird Conference on February 27, 2013
6. Vermillion to Report Results for Fourth Quarter and Full Year 2012 on Wednesday, February 20, 2013
7. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
8. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
9. Interleukin Genetics Reports Third Quarter 2011 Financial Results
10. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
11. Nile Therapeutics Reports 2011 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 19, 2014 Research and Markets  has announced the ... Strategic Business Report" report to their offering. ... Supplies in US$ Thousands by the following Product Segments: Media, Sera, ... the US, Canada , Japan ... and Latin America . Annual estimates and forecasts ...
(Date:8/19/2014)... (PRWEB) August 19, 2014 XenoTech ... fast and cost-effective metabolite production from bioactive small ... chemistry platform, the technology enables convenient and timely ... According to XenoTech’s Vice President of Commercial Operations, ... for assessing clinical risk can be measured directly ...
(Date:8/19/2014)... /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") ... its Oral Amphotericin B (Oral Amp B) drug ... by ImmuneCarta®, the immune monitoring business unit of ... Oral Amp B in reactivating latent HIV viral ... treatment with antiretroviral therapy. Memory ...
(Date:8/18/2014)... , Aug. 18, 2014 BioElectronics ... advanced consumer medical devices said that its ... interviewed by CEOLIVE.TV as part of its ... interview is available at http://ceolive.tv/bioelectronics-corp-otc-biel/biel-videos/2282-ceolive-tv-interview-bioelectronics-corp-otcqb-biel ... explains to investors the unique advantages of ...
Breaking Biology Technology:Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3
... Oct. 2 The Matan Companies has teamed up ... for the development of the National Cancer Institute,s 330,000 ... Research Park in Frederick, Maryland. The state-of-the art ... construction immediately and is slated for delivery in mid ...
... Vermillion, Inc (OTC: VRMLQ.PK) today announced that Eric Fung, M.D., ... Officer. This position will be formally held by Dr. Fung ... Chapter 11 of the U.S. Bankruptcy Code or earlier, if ... interim, Dr. Fung will work as an independent consultant. ...
... J.D. , has opened Stipkala LLC,s new office in Cincinnati, ... Stipkala LLC is an intellectual property law firm with locations ... Guttman has more than nine years of patent law experience, ... entering patent law, Dr. Guttman acquired over ten years of ...
Cached Biology Technology:Matan Companies Teams with Federal Capital Partners to Finance the National Cancer Institute at Riverside Research Park in Frederick, Maryland 2Matan Companies Teams with Federal Capital Partners to Finance the National Cancer Institute at Riverside Research Park in Frederick, Maryland 3Matan Companies Teams with Federal Capital Partners to Finance the National Cancer Institute at Riverside Research Park in Frederick, Maryland 4Vermillion Announces Return of Eric Fung, M.D., Ph.D. 2Vermillion Announces Return of Eric Fung, M.D., Ph.D. 3
(Date:8/19/2014)... . Wind ... large amount of electricity is to be produced with renewable ... be stored during productive periods so that these fluctuations can ... adequate for the purpose. Science and industry are therefore working ... systems that used to be too expensive or unsophisticated to ...
(Date:8/19/2014)... at retail seafood counters in 10 different states ... consumers to unexpectedly high levels of mercury, a ... a fish of the same species, but from ... offense, according to new research by University of ... seafood is essential to allow consumers to choose ...
(Date:8/19/2014)... HOUSTON -- ( Aug. 19, 2014 ) -- Scientists ... how to pick up and transfer single cells using ... tweaked slightly. They describe this engineering feat and preliminary ... Journal of the American Chemical Society . , "Studying ... frontier in current biomedical research," said nanomedicine department. faculty ...
Breaking Biology News(10 mins):Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3Seafood substitutions can expose consumers to unexpectedly high mercury 2Seafood substitutions can expose consumers to unexpectedly high mercury 3Moving single cells around -- accurately and cheaply 2
... marine vibrio bacteria discovered in the last five years, can ... in Edinburgh. , The most common disease of vibrios is ... fatality in humans. Recent interest in this genus of bacteria ... from seawater and marine animals. , New species have been ...
... professor of molecular and human genetics at Baylor College of ... in bacteria stressed by starvation, sometimes resulting in a rare ... a report in the current issue of the journal Molecular ... happens but also show that this only occurs at a ...
... Scientists from the Public Health Agency of Canada - ... of Infectious Diseases - have developed vaccines against the ... be effective in non-human primates. , In a study ... Heinz Feldmann and Dr. Steven Jones of PHAC's National ...
Cached Biology News:Stressed cells spark DNA repair missteps and speed evolution 2Researchers report breakthrough against world’s deadliest viruses 2
... SeeDNA co-precipitant, 250 ul ... color ensures easy pellet ... acid recovery.Chemically inert, compatible ... applications.Simple 5-minute protocol. Category: ...
EDTA, 0.5 M solution, 100 ml. Ethylene diaminetetraacetic acid.Sterile, nuclease-free. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Recombinant Mouse sTNF RII/TNFRSF1B...
Mouse Wnt-11 Affinity Purified Polyclonal Ab...
Biology Products: